Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

NewsGuard 100/100 Score

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from its brentuximab vedotin (SGN-35) and dacetuzumab (SGN-40) programs will be reported at the upcoming 51st American Society of Hematology (ASH) 2009 Meeting and Exposition being held December 5-8, 2009 in New Orleans, Louisiana. A summary of the company’s ASH presentations is below and full abstracts can be accessed at the ASH website at

Brentuximab vedotin data:

The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study

  • Sunday, December 6, 2009, 6:00 p.m. - 8:00 p.m. Central Time (CT)
  • Abstract # 2731 (poster board # II-707)
  • First author: Dr. Michelle Fanale, MD Anderson Cancer Center, University of Texas, Houston, Texas

Dacetuzumab data:

Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase 1b study

  • Sunday, December 6, 2009, 6:00 p.m. - 8:00 p.m. CT
  • Abstract # 2870 (poster board # II-846)
  • First author: Dr. Edward Agura, Baylor Sammons Cancer Center, Dallas, Texas

CD40 pathway activation status predicts response to CD40 targeted therapy in diffuse large B-cell lymphoma

  • Sunday, December 6, 2009, 6:00 p.m. - 8:00 p.m. CT
  • Abstract # 2721 (poster board # II-697)
  • First author: David Dornan, Ph.D., Genentech, Inc.

A phase 1b clinical trial of dacetuzumab in combination with rituximab and gemcitabine: multiple responses observed in patients with relapsed diffuse large B-cell lymphoma

  • Monday, December 7, 2009, 3:30 p.m. CT
  • Abstract # 586
  • Oral presentation in rooms R02-R05
  • First author: Dr. Andres Forero-Torres, Comprehensive Cancer Center, University of Alabama at Birmingham


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Personalizing exercise to fight obesity: Study finds genetics influence effectiveness